

# Laura Pinton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6667362/publications.pdf>

Version: 2024-02-01

13  
papers

1,477  
citations

1162367

8  
h-index

1473754

9  
g-index

13  
all docs

13  
docs citations

13  
times ranked

2847  
citing authors

#	ARTICLE	IF	CITATIONS
1	Myeloid-derived suppressor cell heterogeneity in human cancers. <i>Annals of the New York Academy of Sciences</i> , 2014, 1319, 47-65.	1.8	349
2	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. <i>Blood</i> , 2011, 118, 2254-2265.	0.6	328
3	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. , 2019, 7, 255.		123
4	Complexity and challenges in defining myeloid-derived suppressor cells. , 2015, 88, 77-91.		119
5	Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy. <i>Biomaterials</i> , 2016, 96, 47-62.	5.7	118
6	The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. , 2019, 7, 58.		109
7	Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. <i>Oncotarget</i> , 2016, 7, 1168-1184.	0.8	103
8	Complexity and challenges in defining myeloid-derived suppressor cells. , 2014, , n/a-n/a.		102
9	Methods to Measure MDSC Immune Suppressive Activity <i>In Vitro</i> and <i>In Vivo</i> . <i>Current Protocols in Immunology</i> , 2019, 124, e61.	3.6	35
10	Highlights on Molecular Mechanisms of MDSC-Mediated Immune Suppression: Paving the Way for New Working Hypotheses. <i>Immunological Investigations</i> , 2012, 41, 722-737.	1.0	31
11	Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules. <i>Journal of Nanobiotechnology</i> , 2020, 18, 31.	4.2	30
12	Immunosuppressive activity of tumor-infiltrating myeloid cells in patients with meningioma. <i>Onc Immunology</i> , 2018, 7, e1440931.	2.1	22
13	Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients. <i>Frontiers in Immunology</i> , 2021, 12, 809826.	2.2	8